Elicio Therapeutics Inc
NASDAQ:ELTX

Watchlist Manager
Elicio Therapeutics Inc Logo
Elicio Therapeutics Inc
NASDAQ:ELTX
Watchlist
Price: 11.58 USD -1.7% Market Closed
Market Cap: 189.2m USD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

There is not enough data to reliably calculate the relative value of ELTX.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ELTX Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

N/A
P/S
P/S
Price to Sales
N/A
vs History
vs Industry
9
Median 3Y
0
Median 5Y
0
Industry
2.7
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-1.5
Median 5Y
-1.6
Industry
22.4
Forward
-4.2
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-1.5
Median 5Y
-1.8
Industry
17.1
More Details
53
P/FCFE
P/FCFE
Price to FCFE
53
vs History
0
vs Industry
Median 3Y
-1.9
Median 5Y
-1.9
Industry
23.6
More Details
102.7
P/B
P/B
Price to Book Value
102.7
vs History
0
vs Industry
19
Median 3Y
0.8
Median 5Y
1.1
Industry
2.3
More Details
N/A
EV/S
EV/S
Enterprise Value to Sales
N/A
vs History
vs Industry
10
Median 3Y
0
Median 5Y
0
Industry
2.9
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
12
Median 3Y
0
Median 5Y
0
Industry
5.6
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-1.2
Median 5Y
-1.2
Industry
13.2
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-1.2
Median 5Y
-1.2
Industry
16.6
Forward
-4.1
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-1.3
Median 5Y
-1.3
Industry
15.8
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-1.3
Median 5Y
-1.3
Industry
18
More Details
49.1
EV/IC
EV/IC
Enterprise Value to IC
49.1
vs History
10
vs Industry
7
Median 3Y
4.8
Median 5Y
3.9
Industry
2.1
More Details

Multiples Across Competitors

ELTX Competitors Multiples
Elicio Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Elicio Therapeutics Inc
NASDAQ:ELTX
188.3m USD 0 -3.4 -4 -3.9
US
Eli Lilly and Co
NYSE:LLY
716.1B USD 13.4 51.9 30.7 33.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
429.4B USD 4.7 18.9 14.4 19
CH
Roche Holding AG
SIX:ROG
213.5B CHF 3.5 25.8 9.7 11.3
UK
AstraZeneca PLC
LSE:AZN
185.4B GBP 4.5 30.4 113.7 170
CH
Novartis AG
SIX:NOVN
197B CHF 4.5 18.1 10.9 14.4
DK
Novo Nordisk A/S
CSE:NOVO B
1.5T DKK 4.9 13.8 10.1 11.2
US
Merck & Co Inc
NYSE:MRK
214.2B USD 3.4 13.1 8.4 10
IE
Endo International PLC
LSE:0Y5F
190.5B USD 82.2 -65.2 302.8 759.2
US
Pfizer Inc
NYSE:PFE
141.3B USD 2.2 13.1 7.4 10.2
P/E Multiple
Earnings Growth PEG
US
Elicio Therapeutics Inc
NASDAQ:ELTX
Average P/E: 23.1
Negative Multiple: -3.4 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
51.9
50%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
18.9
28%
0.7
CH
Roche Holding AG
SIX:ROG
25.8
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
30.4
37%
0.8
CH
Novartis AG
SIX:NOVN
18.1
18%
1
DK
Novo Nordisk A/S
CSE:NOVO B
13.8
10%
1.4
US
Merck & Co Inc
NYSE:MRK
13.1
16%
0.8
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -65.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
13.1
30%
0.4
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Elicio Therapeutics Inc
NASDAQ:ELTX
Average EV/EBITDA: 435.4
Negative Multiple: -4 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
30.7
30%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
14.4
8%
1.8
CH
Roche Holding AG
SIX:ROG
9.7
5%
1.9
UK
AstraZeneca PLC
LSE:AZN
113.7
10%
11.4
CH
Novartis AG
SIX:NOVN
10.9
5%
2.2
DK
Novo Nordisk A/S
CSE:NOVO B
10.1
13%
0.8
US
Merck & Co Inc
NYSE:MRK
8.4
7%
1.2
IE
E
Endo International PLC
LSE:0Y5F
302.8
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
2%
3.7
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Elicio Therapeutics Inc
NASDAQ:ELTX
Average EV/EBIT: 1 874.1
Negative Multiple: -3.9 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
33.3
34%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
19
14%
1.4
CH
Roche Holding AG
SIX:ROG
11.3
5%
2.3
UK
AstraZeneca PLC
LSE:AZN
170
22%
7.7
CH
Novartis AG
SIX:NOVN
14.4
11%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
11.2
7%
1.6
US
Merck & Co Inc
NYSE:MRK
10
9%
1.1
IE
E
Endo International PLC
LSE:0Y5F
759.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
10%
1

See Also

Summary
ELTX intrinsic value, competitors valuation, and company profile.
DCF Valuation
ELTX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ELTX stock valuation using valuation multiples.
Wall Street Estimates
ELTX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ELTX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 281,600+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.